A Comprehensive Review of GLP-1 Receptor Agonists and Dual-Incretin Therapies in the Management of Type 2 Diabetes Mellitus

Background: Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease in which the incretin effect is blunted. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist tirzepatide restore incretin signalling and have reshaped treatment goals from glucose control alone toward weight reduction and organ protection. Objective: To summarise the pharmacology, glycaemic and non-glycaemic efficacy, safety, and clinical positioning of GLP-1 RAs and dual-incretin therapies, including agents approaching or reaching the market in 2026. Methods: A narrative review of landmark randomised trials, consensus guidelines, and recent pipeline reports, organised thematically. Findings: Long-acting GLP-1 RAs lower HbA1c by roughly 1 to 1.8 percentage points with clinically meaningful weight loss and a low intrinsic risk of hypoglycaemia. Several agents reduce major adverse cardiovascular events, and semaglutide reduces kidney outcomes in diabetic kidney disease. Tirzepatide produces larger reductions in HbA1c and weight than semaglutide in head-to-head testing. Gastrointestinal adverse effects are the main tolerability issue, while gallbladder disease, pancreatitis, retinopathy changes, and perioperative aspiration require attention. In 2026, the first oral small-molecule agent, orforglipron, was approved for weight management, and triple-agonist and amylin-combination therapies reported promising phase 3 data in T2DM. Conclusion: Incretin-based therapy is now a cornerstone of individualised T2DM management, particularly for people with obesity, cardiovascular, kidney, or liver disease. Access, cost, and long-term durability remain the key challenges.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-14
DOI
https://doi.org/10.5281/zenodo.24216932
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Comprehensive Review of GLP-1 Receptor Agonists and Dual-Incretin Therapies in the Management of Type 2 Diabetes Mellitus

Nikita Ranmal, Kshitija Navale
Zenodo (CERN European Organization for Nuclear Research)
Diabetes Treatment and Management
article

A Comprehensive Review of GLP-1 Receptor Agonists and Dual-Incretin Therapies in the Management of Type 2 Diabetes Mellitus

Nikita Ranmal, Kshitija Navale
article en

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease in which the incretin effect is blunted. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist tirzepatide restore incretin signalling and have reshaped treatment goals from glucose control alone toward weight reduction and organ protection. Objective: To summarise the pharmacology, glycaemic and non-glycaemic efficacy, safety, and clinical positioning of GLP-1 RAs and dual-incretin therapies, including agents approaching or reaching the market in 2026. Methods: A narrative review of landmark randomised trials, consensus guidelines, and recent pipeline reports, organised thematically. Findings: Long-acting GLP-1 RAs lower HbA1c by roughly 1 to 1.8 percentage points with clinically meaningful weight loss and a low intrinsic risk of hypoglycaemia. Several agents reduce major adverse cardiovascular events, and semaglutide reduces kidney outcomes in diabetic kidney disease. Tirzepatide produces larger reductions in HbA1c and weight than semaglutide in head-to-head testing. Gastrointestinal adverse effects are the main tolerability issue, while gallbladder disease, pancreatitis, retinopathy changes, and perioperative aspiration require attention. In 2026, the first oral small-molecule agent, orforglipron, was approved for weight management, and triple-agonist and amylin-combination therapies reported promising phase 3 data in T2DM. Conclusion: Incretin-based therapy is now a cornerstone of individualised T2DM management, particularly for people with obesity, cardiovascular, kidney, or liver disease. Access, cost, and long-term durability remain the key challenges.

Zenodo (CERN European Organization for Nuclear Research)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon